Important note: Information in this article was accurate in May 1984. The state of the art may have changed since the publication date.MMWR Morbidity and Mortality Weekly Report, May 18, 1984 / 33(19);270
Centers for Disease Control and Prevention
A U.S.-manufactured preparation of pentamidine isethionate has undergone satisfactory completion of chemical and biologic tests, and CDC is now able to include this preparation in its claimed investigational exemption for a new drug for treatment of Pneumocystis carinii pneumonia. The Investigational New Drug status for the U.S.-manufactured preparation makes it unnecessary for CDC to distribute the foreign-produced product (pentamidine methanesulfonate) described in the May 4, 1984, issue of the MMWR (33:225-6). The U.S. preparation is being synthesized by Aldrich Chemical Company, Milwaukee, Wisconsin, and packaged for pharmaceutical use by LyphoMed, Inc., Melrose Park, Illinois.
There are two minor differences between the LyphoMed-manufactured product and the previously used May & Baker preparation of pentamidine isethionate. First, the LyphoMed product contains more pentamidine per vial than the May & Baker product (300 mg, compared with 200 mg). Second, the two preparations differ in their physical appearance. May & Baker uses a "dry fill" manufacturing process that leaves a fluffy white powder in the vial, whereas LyphoMed uses a "wet fill" process, followed by lyophilization, leaving a dry "plug" of white powder at the bottom of the vial.
The dosage of the LyphoMed product is the same as for the May & Baker product (4 mg (salt)/kg body weight). Reported by Div of Parasitic Diseases, Div of Host Factors, Center for Infectious Diseases, CDC.
All MMWR HTML documents published before January 1993 electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.
840518
MM3319
Copyright © 1984 - All material in the MMWR Series is in the public domain and may be used and reprinted without special permission; citation as to source, however, is appreciated.
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 1984. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1990, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.